FFA
NTLA icon

Farther Finance Advisors’s Intellia Therapeutics NTLA Stock Holding History

Farther Finance Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.31K Sell
550
-684
-55% -$9.57K ﹤0.01% 4469
2026
Q1 		$16.4K Buy
1,234
+974
+375% +$12.4K ﹤0.01% 3788
2025
Q4 		$2.34K Buy
260
+177
+213% +$2.44K ﹤0.01% 4630
2025
Q3 		$1.43K Hold
83
– – ﹤0.01% 4256
2025
Q2 		$779 Sell
83
-40
-33% -$328 ﹤0.01% 3953
2025
Q1 		$819 Buy
123
+40
+48% +$404 ﹤0.01% 3676
2024
Q4 		$968 Sell
83
-35
-30% -$546 ﹤0.01% 3260
2024
Q3 		$2.42K Sell
118
-5
-4% -$115 ﹤0.01% 2930
2024
Q2 		$2.76K Buy
123
+29
+31% +$690 ﹤0.01% 2659
2024
Q1 		$2.56K Sell
94
-82
-47% -$2.28K ﹤0.01% 2385
2023
Q4 		$5.37K Buy
176
+162
+1,157% +$4.66K ﹤0.01% 1936
2023
Q3 		$443 Sell
14
-4
-22% -$155 ﹤0.01% 2303
2023
Q2 		$734 Hold
18
– – ﹤0.01% 2049
2023
Q1 		$671 Hold
18
– – ﹤0.01% 1931
2022
Q4 		$628 Buy
+18
New +$856 ﹤0.01% 1786

Other funds holding NTLA

CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
GITFIT
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) Warsaw, Poland $249M AUM 37.04% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return

Farther Finance Advisors's NTLA Position: Q2 2026 in Review

Farther Finance Advisors reduced its Intellia Therapeutics (NTLA) stake by 55% in Q2 2026, selling an estimated $9.57K and leaving 550 shares worth $9.31K. The position accounts for ﹤0.01% of the portfolio, ranked #4469.

Farther Finance Advisors first reported a position in NTLA in Q4 2022 and has held it in 15 quarters since. The position peaked at $16.4K in Q1 2026. 38 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Farther Finance Advisors held 550 shares of Intellia Therapeutics worth $9.31K as of Q2 2026.
  • Farther Finance Advisors sold 684 Intellia Therapeutics shares in Q2 2026, an estimated $9.57K.
  • Intellia Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4469 holding.
  • Farther Finance Advisors first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Intellia Therapeutics position peaked at $16.4K in Q1 2026.
  • 38 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.